LIVALO

This brand name is authorized in Brazil, Japan, Singapore, United States

Active ingredients

The drug LIVALO contains one active pharmaceutical ingredient (API):

1 Pitavastatin UNII IYD54XEG3W - PITAVASTATIN CALCIUM

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, and inhibits cholesterol synthesis in the liver. Read about Pitavastatin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIVALO Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AA08	Pitavastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 507612110017502, 507612110017602, 507612110017802
Country: JP	医薬品医療機器総合機構	Identifier(s): 2189016F1028, 2189016F2024, 2189016F3020, 2189016F4027, 2189016F5023, 2189016F6020
Country: SG	Health Sciences Authority	Identifier(s): 15859P, 15860P
Country: US	FDA, National Drug Code	Identifier(s): 66869-104, 66869-204, 66869-404